Two new trials saw no impact of thrombolytics in reducing disability at 90 days, but some positive signals offer hope.

Two randomized trials found that intra-arterial urokinase and tenecteplase did not improve functional outcomes after ...

Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

NDAQ:HUMA) Humacyte Provides Update on Commercial Launch and Pricing of Symvess(TM) (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

Men vs women with spontaneous intracerebral hemorrhage (ICH) have a higher risk for deep bleeds but a lower risk for poor outcomes.

Background: Penetrating craniovertebral junction (CVJ) injuries are rare. The mortality rate of these lesions is extremely high due to the complex anatomy of the region composed of a conglomerate of ...

Clinical question: Among survivors of hemorrhagic stroke, who is at high long-term risk of arterial thrombosis? Background: Patients who survive intracerebral hemorrhage (ICH) are at increased risk of ...

Background: Vertebral artery dissection (VAD ... 32%, P<0.0001), whereas transient ischemic attack (14%) and subarachnoid hemorrhage (10%) were uncommon. Subarachnoid hemorrhage was seen only ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed to replace a patient’s damaged artery following traumatic injuries ...

Background Endovascular arterial embolization (EAE) is an effective treatment for severe epistaxis ... Propensity score matching (PSM) for demographics, comorbidities, and hemorrhage risk factors was ...